PYXS

Pyxis Oncology, Inc.$1.71-0.06 (-3.13%)

Prev Close$1.76·MCap$93.4M·P/E—·Vol275.3K·Yield—

▲

Buys (12M)

$0.00

▼

Sells (12M)

$15.9K

◆

Net Activity

Net Seller

$15.9K

●

Active Insiders

last 12 mo

Over the past 12 months, insider activity at Pyxis Oncology, Inc. (PYXS) has been exclusively selling, with 0 insider purchases totaling $0.00 and 1 insider sale totaling $15.9K. The most recent insider transaction was by HUMPHREY RACHEL (director), who sold $15.9K worth of shares on Mar 25, 2026. Pyxis Oncology, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $93.4M.

PYXS Insider Trading Activity

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Mar 25, 2026	HUMPHREY RACHEL	director	Sell	15,496	$1.03	$15.9K	95,405
Nov 27, 2024	Connealy Pamela Ann	CFO & COO	Buy	88,850	$1.96	$174.4K	1,199,143
Sep 28, 2023	Connealy Pamela Ann	CFO and COO	Buy	8,000	$1.87	$15.0K	818,532
Sep 27, 2023	Connealy Pamela Ann	CFO and COO	Buy	6,426	$1.85	$11.9K	810,532
Sep 27, 2023	Wadhane Jitendra	Chief Accounting Officer	Buy	2,500	$1.87	$4.7K	226,937
Sep 25, 2023	Connealy Pamela Ann	CFO and COO	Buy	12,000	$1.67	$20.0K	804,106
Sep 25, 2023	Wadhane Jitendra	Chief Accounting Officer	Buy	5,000	$1.77	$8.8K	224,437
Sep 22, 2023	Connealy Pamela Ann	CFO and COO	Buy	5,000	$1.74	$8.7K	792,106
Sep 22, 2023	Wadhane Jitendra	Chief Accounting Officer	Buy	2,500	$1.74	$4.3K	219,437
Sep 18, 2023	Sullivan Lara	President and CEO	Sell	8,641	$2.10	$18.2K	2,412,423
Sep 13, 2023	Sullivan Lara	President and CEO	Sell	27,917	$2.27	$63.3K	2,605,182
Apr 25, 2022	Chin Mark		Sell	1,745,761	$3.05	$5.32M2.8% OS	0Exit
Dec 9, 2021	Cline Darren S	Director	Buy	10,000	$9.39	$93.9K	10,000
Nov 19, 2021	Civik Thomas	Director	Buy	15,700	$12.74	$200.0K	15,700
Oct 15, 2021	Chin Mark		Buy	312,500	$16.00	$5.00M	1,745,761
Oct 15, 2021	Cormorant Asset Management, LP		Buy	450,000	$16.00	$7.20M0.7% OS	1,118,854+67%

PYXS Insider Buying Activity

The following table shows recent insider purchases of Pyxis Oncology, Inc. (PYXS) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Nov 27, 2024	Connealy Pamela Ann	CFO & COO	Buy	88,850	$1.96	$174.4K	1,199,143
Sep 28, 2023	Connealy Pamela Ann	CFO and COO	Buy	8,000	$1.87	$15.0K	818,532
Sep 27, 2023	Connealy Pamela Ann	CFO and COO	Buy	6,426	$1.85	$11.9K	810,532
Sep 27, 2023	Wadhane Jitendra	Chief Accounting Officer	Buy	2,500	$1.87	$4.7K	226,937
Sep 25, 2023	Connealy Pamela Ann	CFO and COO	Buy	12,000	$1.67	$20.0K	804,106
Sep 25, 2023	Wadhane Jitendra	Chief Accounting Officer	Buy	5,000	$1.77	$8.8K	224,437
Sep 22, 2023	Connealy Pamela Ann	CFO and COO	Buy	5,000	$1.74	$8.7K	792,106
Sep 22, 2023	Wadhane Jitendra	Chief Accounting Officer	Buy	2,500	$1.74	$4.3K	219,437
Dec 9, 2021	Cline Darren S	Director	Buy	10,000	$9.39	$93.9K	10,000
Nov 19, 2021	Civik Thomas	Director	Buy	15,700	$12.74	$200.0K	15,700
Oct 15, 2021	Chin Mark		Buy	312,500	$16.00	$5.00M	1,745,761
Oct 15, 2021	Cormorant Asset Management, LP		Buy	450,000	$16.00	$7.20M0.7% OS	1,118,854+67%

PYXS Insider Selling Activity

The following table shows recent insider sales of Pyxis Oncology, Inc. (PYXS) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Mar 25, 2026	HUMPHREY RACHEL	director	Sell	15,496	$1.03	$15.9K	95,405
Sep 18, 2023	Sullivan Lara	President and CEO	Sell	8,641	$2.10	$18.2K	2,412,423
Sep 13, 2023	Sullivan Lara	President and CEO	Sell	27,917	$2.27	$63.3K	2,605,182
Apr 25, 2022	Chin Mark		Sell	1,745,761	$3.05	$5.32M2.8% OS	0Exit